In an open-label phase 1/2 trial (NCT03598608), the combination of favezelimab (an anti-LAG-3 antibody) and pembrolizumab demonstrated promising antitumor activity in heavily pretreated R/R cHL patients who had progressed after prior PD-1 blockade. The gene discussed is LAG3; the disease is classic Hodgkin lymphoma.